Canada Markets open in 1 hr 55 mins

Minerva Surgical, Inc. (UTRS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
5.54-0.28 (-4.81%)
At close: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close5.82
Open5.82
Bid5.20 x 1000
Ask9.51 x 800
Day's Range5.23 - 6.20
52 Week Range4.28 - 10.37
Volume64,168
Avg. Volume210,543
Market Cap159.64M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-20.72
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.50
  • GlobeNewswire

    Minerva Surgical Reports Preliminary Fourth Quarter and Full Year 2021 Revenue

    SANTA CLARA, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a medical device company that has established a broad product line of commercially available, minimally invasive medical devices that address the most common causes of abnormal uterine bleeding (AUB) as alternatives to hysterectomy, today reported preliminary unaudited fourth quarter and full year 2021 revenue expectations. Preliminary Fourth Quarter and Full Year 2021

  • GlobeNewswire

    Minerva Surgical to Present at the 40th Annual J.P. Morgan Healthcare Conference

    SANTA CLARA, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a woman’s health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that its management will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 11:15 a.m. Eastern Time. A live audio webcast and replay of the presentation may be accessed for 30 days through the “Recent Events” section of Minerva’s website at http://ir.minervasu

  • GlobeNewswire

    Minerva Surgical, Inc. Third Quarter 2021 Financial Results

    SANTA CLARA, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a medical device company that develops therapeutic devices that treat abnormal uterine bleeding in a minimally invasive manner, today reported financial results for the third quarter ended September 30, 2021 and provided full-year 2021 revenue guidance. Recent Business Highlights Reported third quarter 2021 revenues of $12.5M, compared with revenues of $12.3M in third q